Anti-Human CXCR4 (Clone 12G5) – Biotin

CP-MAC-infected Sup-T1 cells

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

12G5 activity is directed against human CXCR4 (CD184; Fusin).

CXCR4 is expressed in various organs including ovary, bone marrow, kidney, lung, small intestine, spleen, lymph nodes, brain, stomach, liver, thymus, heart, and pancreas as well as on the surface of endothelial mature and precursor cells and pericytes.

CXCR4 is a G-protein coupled receptor that binds the chemokine CXCL12¹. Chemokines are small 8-12 kDa proteins that mediate cell migration and arrest, homing and trafficking of leukocytes in bone marrow and lymphoid organs, tissue formation, cytoskeletal rearrangement, and immune cell recruitment to inflammation. Additionally, chemokines are expressed by cancer cells, where they enhance tumor angiogenesis and development. CXCR4 is the chemokine receptor most abundantly expressed² and most frequently detected³ in various cancer types, being present in malignant cell subpopulations in primary tumors as well as sites of metastasis. CXCR4 is involved in tumor cell proliferation and migration² and is involved in leukocyte chemotaxis in several autoimmune diseases¹. CXCR4 also acts as an alternative receptor for some isolates of HIV-2 in the absence of CD4⁴. CXCR4 expression is regulated by HIF-1α, IL-5, IFN-γ, TGF-β, and IL-17A¹.

12G5 was produced by immunizing Balb/c mice with CP-MAC-infected Sup-T1 cells⁴. Hybridomas were generated and screened for the ability to inhibit CP-MAC-induced syncytium induction on Sup-T1 cells.

12G5 binds specifically to both human and nonhuman cells that express recombinant CXCR4⁴. 12G5 inhibits CD4-independent infection by some HIV-2 isolates, and preincubating cells with 12G5 abolishes syncytium formation. HIV-2/vcp-infected cells display a marked and selective reduction in 12G5 binding. 12G5 also inhibits induction of cell-to-cell fusion of CXCR4⁺ RD/CD4 cells by HIV-1 and HIV-2 strains⁵.

1. Mousavi A. Immunol Lett. 217:91-115. 2020.
2. Barbieri F, Bajetto A, Thellung S, et al. Expert Opin Drug Discov. 11(11):1093-1109. 2016.
3. Bajetto A, Barbieri F, Dorcaratto A, et al. Neurochem Int. 49(5):423-432. 2006.
4. Endres MJ, Clapham PR, Marsh M, et al. Cell. 87(4):745-756. 1996.
5. McKnight A, Wilkinson D, Simmons G, et al. J Virol. 71(2):1692-1696. 1997.
6. Fischer T, Nagel F, Jacobs S, et al. PLoS One. 3(12):e4069. 2008.
7. Volin MV, Joseph L, Shockley MS, et al. Biochem Biophys Res Commun. 242(1):46-53. 1998.
8. Berndt C, Möpps B, Angermüller S, et al. Proc Natl Acad Sci U S A. 95(21):12556-12561. 1998.
9. Ullrich CK, Groopman JE, Ganju RK. Blood. 96(4):1438-1442. 2000.
10. Murga M, Fernandez-Capetillo O, Tosato G. Blood. 105(5):1992-1999. 2005.